Closing Remarks

5/16/02


Click here to start


Table of Contents

Closing Remarks

Criteria for Approvability

Key Conclusions from European Pivotal Efficacy Studies

Excerpts from NIAAA Letter to FDA Division (May 9, 2000)

Interpretation of Acamprosate U.S.A. Multicenter Trial

Acamprosate, 333 mg tablets

The Toll of Alcohol Dependence

Lipha Pharmaceuticals, Inc.

Author: Maureen Galie